Healthpeak (DOC) Q3 2026 Earnings Call Transcript

Healthpeak raised full-year 2026 adjusted FFO guidance for the third time, by $0.02 per share at the midpoint to $1.76–$1.78, and lifted same-store cash NOI guidance by 50 basis points to 0.5%–2.0%. Lab occupancy rose 130 basis points sequentially to 79.8%, while Janus Living reported 26% same-store NOI growth; management cited stronger leasing and acquisition opportunities. A key offset is $1.4 billion of 2027 debt maturities refinancing at rates above the roughly 3% cost of maturing debt.

Analysis

DOC’s improvement is real operationally, but the earnings payoff is delayed: lab leases need roughly a year or more to commence, while acquisition vacancy and tenant-improvement spending arrive before stabilized rent. The key asymmetry is that management is buying assets at a low in-place yield and underwriting a much higher stabilized yield; that return depends on converting active discussions and nonbinding LOIs into creditworthy leases. AI/robotics demand may help absorb specialized space, but should not yet be capitalized as durable biotech rent growth. The 2027 debt reset is the nearer-term counterweight: replacing low-coupon debt with market-rate financing can absorb early NOI gains, so occupancy progress need not translate quickly into per-share FFO growth.

Consensus may overread reported growth at JAN: its rapid expansion is acquisition-led, and consolidated contributions to DOC should be assessed net of purchase costs, capital needs, and funding. Conversely, the lab recovery could be underappreciated if positive leasing converts to cash rent while new supply remains uneconomic. The thesis breaks if lab occupancy stalls, lease negotiations fail to become executed leases, or refinancing costs push leverage/interest expense materially higher. Management’s pipeline and stabilized-yield claims remain company estimates, not realized returns.

Key Decisions for Investors

• DOC: Favor a measured, staged long on weakness rather than chasing the earnings-guidance raise. Add only as lab leases commence and cash NOI confirms conversion; trim if occupancy gains reverse or leasing activity fails to convert over the next 2–3 quarters.
• Monitor the 2027 refinancing plan as the principal near-term catalyst/risk: verify final borrowing mix, all-in coupon, and interest expense versus the expiring debt. A materially higher cost or leverage deterioration would weaken the long thesis even if leasing remains firm.
• Treat the lab acquisitions as a watch item, not yet proof of 9%–10% returns. Track executed leases versus LOIs, tenant credit, concessions/TI outlays, and time to occupancy; failure to convert the reported pipeline within management’s 2–3-year lease-up window would falsify the value-creation case.
• For JAN, avoid extrapolating acquisition-driven revenue and EBITDA growth as organic momentum; reassess using same-store occupancy/NOI and incremental funding economics.